Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Atossa Therapeutics, Inc. ATOS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
56/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$10.00
+74.2%

Atossa Therapeutics, Inc. (ATOS) is a Biotechnology company in the Healthcare sector, currently trading at $5.74. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ATOS = $10 (+74.2% upside).

Valuation: ATOS trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.

Net income is $35M (loss), growing at -11.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $39M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.53 (strong liquidity). Debt-to-assets is 0%. Total assets: $48M.

Analyst outlook: 4 / 5 analysts rate ATOS as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$10.00
▲ 74.22% Upside
Average Price Target
The 12-month price target for Atossa Therapeutics, Inc. is $10.00.

ATOS SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATOS

✓
VALUE Pass
100/100
ATOS trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25). Forward PEG 0.04 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.08. Analyst consensus target is $10, implying +74.2% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ATOS: +0%/yr revenue is, -11.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ATOS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ATOS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 4 / 5 analysts rate ATOS as buy (80%). Analyst consensus target is $10 (+74.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.76-19.35
Volume100.04K
Avg Volume (30D)138.52K
Market Cap$49.43M
Beta (1Y)1.35
Share Statistics
EPS (TTM)-4.04
Shares Outstanding$8.61M
IPO Date2012-11-08
Employees15
CEOSteven C. Quay
Financial Highlights & Ratios
Gross Profit$-16K
EBITDA$-37.13M
Net Income$-34.77M
Operating Income$-37.14M
Total Cash$41.3M
Net Debt$-41.3M
Total Assets$47.61M
Price / Earnings (P/E)-1.4
Analyst Forecast
1Y Price Target$10.00
Target High$10.00
Target Low$10.00
Upside+74.2%
Rating ConsensusBuy
Analysts Covering5
Buy 80% Hold 20% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS04962H7044

Price Chart

Track all markets on TradingView
ATOS
Atossa Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
3.76 52WK RANGE 19.35

People Also View

NVAX
NVAX
Novavax, Inc.
$8.69
+3.58%
 OCGN
OCGN
Ocugen, Inc.
$1.95
+8.33%
 PALI
PALI
Palisade Bio, Inc.
$2.34
+13.59%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$14.34
+7.42%
 VXRT
VXRT
Vaxart, Inc.
$0.71
+4.41%
 INO
INO
Inovio Pharmaceuticals, Inc.
$1.19
+7.21%
 IBIO
IBIO
iBio, Inc.
$2.10
-4.11%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message